Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Re-Models Around Disease Areas, Pulls Together R&D And Commercial

This article was originally published in PharmAsia News

Executive Summary

Roche is taking a dual approach in reorganizing its global R&D business by centering on key disease areas and consolidating its full operations, from R&D to marketing, along those lines

You may also be interested in...



Pfizer’s Manufacturing Cost-Cutting May Leave Little Capacity For Growth

Following its restructuring, Pfizer's in-house manufacturing capacity will support approximately $48 billion in sales

“One Pfizer” Restructuring Initiative Divides R&D And Sales Operations

Pfizer's latest corporate restructuring represents a shift away from its recent alignment of research & development and commercialization operations

Amgen Sizes Up Strategy: Small-Scale Acquisitions, Large-Scale R&D

Amgen's growth strategy calls for heavy investment in research & development and targeted agreements to expand its pipeline, rather than large-scale acquisitions, CEO Kevin Sharer said

UsernamePublicRestriction

Register

SC065976

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel